Pictor key facts
as of Oct 2026- Developer of a proteomics platform designed to detect multiple biomarkers simultaneously for comprehensive biological analysis.
- Pictor is valued at approximately $85.6M as of Oct 2026 (last reported valuation).
- It has raised $22.6M.
- Notable investors include K1W1, New Zealand Growth Capital Partners, Arc Angels, Aspire NZ Seed Fund, Callaghan Innovation — 15 tracked in total.
- Status: Privately Held (backing).
Pictor's last reported valuation, Dec 2022. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Pictor: the Monday email on marks, rounds and moves
Pictor funding rounds
No funding rounds for Pictor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Pictor
15+Pictor valuation
Pictor's last reported valuation was $85.6 million in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.
Pictor investors
15 investors are on record for Pictor, including K1W1, New Zealand Growth Capital Partners, Arc Angels and Aspire NZ Seed Fund.
About Pictor
Developer of a proteomics platform designed to detect multiple biomarkers simultaneously for comprehensive biological analysis. The company offers an AI-integrated, end-to-end workflow, enabling clinical trials, diagnostics manufacturers, clinical labs, drug developers, and veterinary clinics to gain broader insights with reduced cost and complexity
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2005
- Employees
- 25
- Website
- pictordx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.